PRLR

Across TCGA pan-cancer cohorts, PRLR Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRLR data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher PRLR Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRLR expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

SARC, SCLC, and LUAD are the cancer types where PRLR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.079	0.615	<.001	12	view →
SCLC	OS	Median	All	0.192	0.660	.003	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
UCEC	DFS	Median	All	0.955	0.622	.033	2	view →
SKCM	OS	Median	All	0.865	0.770	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRLR–SARC (DFS)

Open the SARC breakdown →